Introduction. Hypertrophic cardiomyopathy (HCM) is a complex disorder and genetically transmitted cardiac disease with a diverse clinical course. The objective of the present study was to examine the association of the T704C polymorphism of exon 2 of the angiotensinogen (AGT) gene with HCM in a South Indian population from Andhra Pradesh. Subjects and methods. One-hundred and fifty HCM (90 sporadic hypertrophic cardiomyopathy [SHCM] and 60 familial hypertrophic cardiomyopathy [FHCM]) patients and 165 age-and sex-matched normal healthy controls without known hypertension and left ventricular hypertrophy were included in the study. DNA was isolated from peripheral leukocytes and the region of interest in the AGT gene bearing a missense mutation methionine to threonine substitution at codon 235 (M235T) of exon 2, was amplified by polymerase chain reaction (PCR). The PCR products were subjected to restriction digestion with the enzyme SfaNI. Results. Significant differences were detected in genotypic distribution (p = 0.04) as well as the allelic frequency (p = 0.003) between the SHCM patients and controls. The polymorphism did not show any association with FHCM. Conclusion. Our results suggest that the T allele of the AGT gene is significantly associated with SHCM in a South Indian population from Andhra Pradesh. However, we did not find significant association of this polymorphism with FHCM.
Introduction
Hypertrophic cardiomyopathy (HCM) is a genetically trans mitted cardiovascular disease with heterogeneous clinical features, with predominant involvement of the left ventricle, in the absence of other leading conditions such as hyperten sion. 1 The disease remained largely unrecognised as a clini cal phenotype until the second half of the 20th century, when initial reports in the 1950s detailed pathological phe notypes along with familial inheritance. The prevalence of the disease in the general population is 1 in 500 carrying an annual cardiovascular mortality rate of 0.7-1.4%. 2 Sudden cardiac death is a frequent complication with an annual inci dence of 2-3% occurring in the young. 3, 4 HCM occurs both as a familial disorder, inherited as an autosomal dominant trait, and as a sporadic disease which can develop due to de novo mutations. Both familial and sporadic forms of HCM represent different parts of the spectrum of the same con dition. 5 Based on the phenotypic patterns, the HCM phe notypes are divided into asymmetric septal hypertrophy (ASH), apical hypertrophy (AH), diffuse hypertrophy (DH) and left ventricular free wall hypertrophy (FH).
The aetiology of the disease is multifactorial with the majority of cases occurring due to secondary mutations (100 mutations) in sarcomere myofilament genes which contribute to heterogeneity in disease phenotype. The first described gene was the one encoding for cardiac-βmyosin heavy chain, the major contractile protein of the cardiac sarcomere. 6 Identification of mutations in another eight sarcomeric components such as cardiac myosin binding proteinC, αtropomyosin, cardiac troponin T, ventricular myosin essential and regulatory light chains, cardiac tro ponin I, cardiac αactin and titin in HCM patients led to the postulation that HCM results from defects in the sarcomeric proteins and it was subsequently referred to as a 'disease of the sarcomere'. 712 To date, 13 gene mutations coding for sarcomeric proteins have been found in patients with HCM. 13 The genes encoding for the sarcomeric pro teins involved in HCM are located on different chromo somes. A variability of cardiac phenotype and clinical course occurs although the same disease mutation is seen in family members suggesting that the disease course is not solely dependent on the pathogenic gene but may also be modified by factors other than the genetic defect such as the modifier genes or environmental influences. 14 Among the known potential modifier genes are those encoding for renin-angiotensin-aldosterone system (RAAS). The RAAS system plays a central role in cardiovascular system which contributes to ventricular hypertrophy through effects mediated by circulating angiotensin and also local activa tion of RAAS in the myocardium. 15 The RAAS has been shown to be associated with hypertrophy in familial HCM. However, the degree of its contribution is shown to be greater in sporadic HCM than familial HCM. 16, 17 The angiotensinogen (AGT) gene regulates the expression of angiotensinogen, a glycoprotein produced by the liver and its cleavage by renin liberates angiotensin I which is con verted into angiotensin II by angiotensin converting enzyme (ACE). The TT genotype of angiotensinogen might be a genetic marker of electrocardiographically determined left ventricular hypertrophy (LVH) since a positive association has been reported between angiotensinogen M235T polymor phism and HCM. 18 The polymorphism has also been associ ated with other cardiovascular diseases such as myocardial infarction, coronary atherosclerosis and hypertension. 1926 There are no reports of the association of T704C poly morphism in AGT gene with HCM from India. Therefore, the aim of the present study was to analyse the association of this polymorphism with HCM in a South Indian popula tion from Andhra Pradesh.
Materials and methods

Subjects
The study cohort consisted of 150 HCM patients (male:female = 106:44) who were diagnosed by echocardi ography at Osmania General Hospital, Gandhi General Hospital and UshaMullapudi Cardiac centre from 2005 to 2009. One hundred and sixty five age and sexmatched healthy subjects (male:female = 116:49) served as controls. They were blood donors from the same hospitals. The present study was approved by the institutional ethical committee and all eligible participants gave their written informed consent in accordance with study protocols approved by the study hospitals; before the echocardio graphic examination and peripheral blood sampling. Patients with thyroid disease, hypertension and myocardial infarction which may cause LVH were excluded from the study. Owing to incomplete and agerelated penetrance and also to avoid misunderstanding of results, participants who were less than 30 years of age, were also excluded from the study. The distribution of LVH was assessed primarily in the parasternal short axis and long axis two and four cham ber views. The diagnosis of LVH was based on local or diffuse hypertrophy in the free wall, apical wall or interven tricular septum of the left ventricle.
The HCM patients were classified into two groups, i.e. sporadic (SHCM) and familial (FHCM) types. Ninety patients belonged to the SHCM (had no family history of the disease) and remaining 60 patients belonged to the FHCM group (had evident family history).
Genotype determination
Genomic DNA was isolated from peripheral blood leuko cytes using the salting out method. 27 The M235T polymor phic site of exon2 region of AGT gene was assessed by PCR (Thermal cycler, Eppendorf, USA) and a restriction fragment length polymorphism technique. The primers used were 5`GATGCGCACAAGGTCCTGTC3' (forward) and 5` CAGGGTGCTGTCCACACTGGCTCGC 3` pub lished previously. 18 The most 3` guanosine residue in the longer oligonucleotide is mismatched with genomic DNA which (depending on the sequence) creates a SfaNI restric tion site during amplification. The PCR was performed in standard buffer (10× reactive buffer) and each 25 µl of PCR reaction contained 100 ng genomic DNA, 0.2 µmol/l of each primer, 400 µM each dNTP and 1 unit of Taq polymer ase (Bangalore Genei, India). The PCR reaction consisted of initial denaturation at 95°C for 5 min followed by 29 cycles of denaturation at 94°C for 30 sec, annealing at 60°C for 1 min, followed by final extension at 72°C for 1 min. The PCR products were 303 bp in size. Ten microlitres of PCR product was diluted to 20µl in the recommended restriction buffer containing 0.5 U of SfaNI (Fermentas). The restriction digestion was performed at 37°C for 5 hours. The products were subjected first to 2% agarose gel 
Statistical analysis
Values were expressed as mean ± standard deviation (SD). Continuous data were analysed using single factor analysis of variance (ANOVA) using SPSS version 14.0 for Windows statistical package. Hardy-Weinberg equilibrium was tested for the AGT gene polymorphism. The genotypes were in agreement with the law. The association between the geno types and HCM was examined by odds ratio with 95% con fidence intervals and chisquare analysis. All of the statistical tests were considered significant at p < 0.05.
Results
The present study group included 150 HCM patients (males: females = 70.6%:29.4%) and 165 controls (males:females = 70.3%:29.6%). The demographic and clinical characteristics of the subjects have been summarised in table 1. The mean age in patients and controls was 52.6 ± 8.5 and 50.4 ± 9.2, respectively. Forty percent of the patient group had a family history of HCM. The percentage of smokers and alcohol drinkers was significantly lower in patients in comparison with controls. The systolic and diastolic blood pressures were within normal limits in all of the subjects and there was no difference in the patients and control group when com pared. The averages of the left ventricular maximum wall thickness showed no difference, it was observed as normal (<11 mm). For the angiotensinogen TC polymorphism, the geno typic and allelic frequencies of patients and controls have been presented in table 2. The frequency of TT, MT and MM genotypes in male patients with HCM were 51.8% (55 of 106), 39.6% (42 of 106) and 8.4% (9 of 106), respec tively. In female patients these were 43.1% (19 of 44), 45.4% (20 of 44) and 11.3% (5 of 44), respectively. The TT, MT and MM genotypes of the AGT gene were 58.4% (53 of 90), 43.3% (34 of 90) and 2.2% (3 of 90) in patients with SHCM and 28.3% (17 of 60), 56.6% (34 of 60) and 15% (9 of 60) in patients with FHCM. The T allele associated sig nificantly with SHCM. For T vs M allele, χ 2 was 8.7 (OR 1.87, 95% CI 1.23-2.84, p = 0.003) and for TT genotype vs MM genotype, χ 2 was 4.04 (OR 4.07, 95% CI 1.12-14.83, p = 0.04) (table 3) . No significant association of T allele was found with FHCM: T vs M allele, χ 2 was 2.71 (OR 0.69, 95% CI 0.45-1.07, p = 0.09) and TT vs MM geno type, χ 2 was 2.82 (OR 0.43, 95% CI 0.16-1.16, p = 0.09) (table 4). The frequency of T allele was 0.68 in HCM patients and 0.65 in healthy controls. 
Discussion
The cardiac renin-angiotensin system (RAS) plays an important role in the development of LVH because of its action on cell proliferation and regulation in part of the expression of cardiac hypertrophy. It has been suggested that the TT genotype of AGT gene might be a genetic marker in electrocardiographically determined LVH in HCM patients and data also suggests that angiotensinogen T235 allele fre quencies differ among hypertensive populations. 2832 Angiotensinogen is a glycoprotein containing 485 amino acids produced by the hepatocytes and released into the cir culation. 33 It is converted into angiotensin I by the enzyme renin and further cleaved into biologically active vasocon strictive peptide angiotensin II of the RAS. Since cardiac RAS plays an important role in the development of cardiac hypertrophy, the concentration of angiotensinogen is rate limiting in the production of angiotensin I, which plays an important role in the regulation of angiotensin II produc tion. The de novo mutations have been reported to cause both the familial and sporadic forms of HCM.
Previous reports have suggested a strong association of smoking and alcoholism with cardiovascular diseases espe cially alcoholic cardiomyopathies. 34 However, in the present study we did not find an association of these con founding risk factors with the disease, strengthening the genetic aetiology of the condition.
AGT is shown to be involved in essential hypertension, renal tubular dysgenesis, nonfamilial structural atrial fibrillation and LVH. It exhibits a potent myotrophic action. There are certain controversial reports on the association of AGT gene M235T polymorphism with HCM. Some studies have reported a positive association 16, 18, 35 whereas others did not find any association with HCM. 3638 There are reports of FHCM 39 as well as SHCM from India. 17 The present study was carried out with an aim to find the association of AGT M235T polymorphism with HCM in a South Indian population from Andhra Pradesh. In the present study we observed that the TT genotype as well as T allele associated significantly with HCM (p < 0.05). Kawaguchi also reported the same association in a Japanese population. 16 However, neither the TT genotype nor T allele associated significantly with FHCM (p > 0.05). Further the SHCM had a high T allele frequency in com parison with FHCM patients. The lack of association of this polymorphism with FHCM shows that this mutation is associated with SHCM rather than FHCM where the muta tions in sarcomeric genes have been found to be associated with the disease.
The familial and sporadic forms of HCM indicate that they are two different factors with the same condition and certainly have very important implications in relation to risk factor stratification and also genetic counselling. The RAAS may also be associated with FHCM. However, its association is observed more in the SHCM which suggests that SHCM is partially determined by genetic disposition. The other genes of RAAS such as ACE 40 have also been shown to cause HCM. Perkins et al. 36 reported that DD genotype of ACE may be the key determinant in the pheno typic expression of HCM since tissue levels of ACE are greater in patients with this genotype. According to Marian et al. 41 it may lead to sudden cardiac death. Schunkert et al. 42 found that HCM subjects with D allele had signifi cant increase in LVH. Rai et al. 17 have also found ACE I/D polymorphism to be associated with HCM and dilated car diomyopathy in Indian population. These results also sug gest the influence of RAAS in cardiac hypertrophy in HCM especially in sporadic cases.
Conclusion
The T allele of AGT gene is a risk factor especially in spo radic cases of HCM in the study population. However, fur ther larger cohorts, multicentre populationbased studies are required to confirm the association of T allele with the disease.
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